Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Click here to view social media version of this release.
Click here to visit the Cord Blood America Social Media Newsroom.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
Cord Blood America Inc. (OTCBB: CBAI | Quote | Chart | News | PowerRating) through its subsidiaries, provides private cord blood stem cell preservation services to families in the United States. It also engages in collecting, processing, and preserving peripheral blood and adipose tissue stem cells, which allows individuals to privately preserve their stem cells for potential future use in stem cell therapy. In addition, the company engages in the collection, transportation, testing, and preservation of umbilical cord blood. Further, it creates direct response television and radio advertising campaigns, including media placement and commercial production; involves in the placement of advertising in television and radio outlets; and production of advertising content, including television commercials and radio copy. Additionally, the company engages in procuring and setting up call centers; editing, dubbing, and distribution of radio and television commercials; and procuring and placing print advertising, as well as provides advertising and marketing consulting services relating to the customer''s marketing campaign. The company is headquartered in Santa Monica, California. With 1.58 billion shares outstanding and 67,300 shares declared short as of June 2009, there is no longer a failure to deliver in shares of CBAI. According to quarterly data provided by the SEC, there were still 4,342,860 shares of CBAI that were failing-to-deliver as of September 18, 2007.
SANTA MONICA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today it has retired $2.53M of long-term debt.
"The two notes signed in February and March of 2007 respectively, between CBAI and the Shelter Island Opportunity Fund (SIOF), have been retired as of August 3, 2009. With this debt retirement, CBAI has only the put option agreement obligation with SIOF remaining on its balance sheet. Cord Blood America regards this as a key milestone on its path to being able to operate debt free," said Matthew Schissler, Cord Blood America Founder and CEO. "Shelter Island provided us with the capital to purchase CorCell, which is the first licensed family cord blood banking company in the United States. Using their financing allowed us to establish CBAI as one of the largest domestic stem cell storage companies. Our obligation was to pay the notes in full before the February 28, 2010 maturity date. We are happy to have met the obligation and have saved a significant amount of interest payments because of early payoff."
"We have repeatedly said that decreasing debt would be one of our significant items to focus on in 2009," said Mr. Schissler. "Eliminating debt makes our financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development."
LOS ANGELES, CA -- (Marketwire) -- 08/07/09 -- Bioterrorism detection, stem cell storage lab, "Dead of Night" movie and mortgage advice; this week on MoneyTV, hosted by anchor Donald Baillargeon. MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring informative interviews with company CEOs, providing insights into their operations and outlooks for their futures.
Free information packages from the featured companies can be requested by sending an email to firstname.lastname@example.org.
The television program can also be viewed online immediately at www.moneytv.net.
Featured companies on this week's program include:
Cord Blood America, Inc. (OTCBB: CBAI) CEO Matthew Schissler talked about the company's new laboratory in Las Vegas, scheduled to go online in October.
ja hier geht sicher etwas. Das Unternehmen ist seit Jahren im Aufbau, Kundenzahlen steigen langsam aber stetig, Schulden werden mit Nachträglichkeit reduziert, neues Labor und kein Regierungsveto mehr wie zu Bushzeiten (Betrifft ja CBAI nicht direkt, da die nur lagern, sondern was man mit dem Cryozellen machen kann) . Wenn man sich den dt. Konkurrenten Vita 34 ansieht (aktie bei ca. Euro) kann man ablesen, dass die Lagerung von Stammzellen, Nabelschnurblut etc. in Dtl. groß im kommen ist (und das trotz Zweifler). Da der Markt in den USA immens größer ist, Amerikanische Bürger tendentiell noch einfach manipulierbar sind und auf Trends aufspringen, denke ich wir haben es mit einer kommenden Boombtanche zu tun.
Zwecks R/S: Diluttion ist schon krass bei CBAI. immer wenn ich nachkaufe werden in Berlin 666.667 Aktien (exakt 2000Euro) angeboten. Kaum ist meine Order durch sind plötzlich wieder die fehlenden Stücke auf 666.667 aufgestockt. Die Kurssprünge der Aktie kamen bis jetzt immer zustande wenn die Dilution kurz ausgesetzt wurde.
Positiv anzumerken ist das relativ hohe volumen in den USA und langsam auch in DTL. D.h.Interesse ist da, wir müssen halt ausharren bis alle Aktien im Umlauf sind. Je nach entwicklung des Kurses wird der R/S wohl kleiner ausfallen als zb. bei Genta. Bin mit 200k drin und habe vor nach dem Urlaub auf 1Mio oder mehr aufzustocken. Diese Aktie wird einschlagen, die Frage ist nur wann.
Toronto (aktiencheck.de AG) - Die Analysten von RBC Capital Markets stufen die Aktie von Angiotech Pharmaceuticals (Profil) unverändert mit "outperform" ein. Das Kursziel werde von 4,00 auf 2,00 USD gesenkt. (24.09.2008/ac/a/u)